Chinese health officials Monday urged patients who have recovered from the coronavirus to donate blood so that plasma can be extracted to treat others who are critically ill.
Drugmakers are racing to develop a vaccine and treatment for the epidemic, which has which killed 1,770 people and infected over 70,500 people across China.
Plasma from patients who have recovered from a spell of pneumonia triggered by COVID-19 contains antibodies that can help reduce the virus load in critically ill patients, an official from China's National Health Commission told a press briefing Monday.
"I would like to make a call to all cured patients to donate their plasma so that they can bring hope to critically ill patients," said Guo Yanhong, who heads the NHC's medical administration department.
Eleven patients at a hospital in Wuhan -- the epicentre of the disease -- received plasma infusions last week, said Sun Yanrong, of the Biological Center at the Ministry of Science and Technology.
"One patient (among them) has already been discharged, one is able to get off the bed and walk and the others are all recovering," she said.
The call comes days after China's state-owned medical products maker reported successful results from its trial at Wuhan First People's Hospital.
China National Biotec Group Co. said in a post on its official WeChat account that severely ill patients receiving plasma infusions "improved within 24 hours".
"Clinical studies have shown that infusing plasma (from recovered patients) is safe and effective," Sun said.
Blood doners will undergo a test to ensure that they are not carrying the virus, said Wang Guiqiang, chief physician at Peking University First Hospital.
"Only plasma is taken, not all the blood," he said.
"Other components of the blood including red blood cells and platelets will be infused back into the donors.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
